Exubera Efficacy In Type 1 Diabetes "Intensive" Control Questioned By FDA

Pfizer/Sanofi trial shows only 23% of Type 1 diabetes patients receiving inhaled insulin achieved standard of care for glycemic control, FDA tells advisory committee in briefing materials for Sept. 8 meeting.